Anne M. Rompalo, MD

CRS:

JHU

Role:

Investigators

Position:

HPTN Site Leader

Email:

arompalo@jhmi.edu

Anne M. Rompalo, M.D., Sc.M.  Dr. Rompalo is a Professor of Medicine and Gynecology at the Johns Hopkins University School of Medicine (JHUSOM), with joint appointments in Epidemiology, International Health and Population, Family and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health.  She is Medical Director of the CDC-sponsored Sexually Transmitted Diseases (STD)/HIV Prevention Training Center at Johns Hopkins (PTC), and has previously been Acting Medical Director of the Baltimore City Health Departments STD Clinics and Medical Director of the Office of Population Affairs Male Training Center.  She has over 15 years of experience as the Medical Director of the STD/HIV PTC, and has been a key investigator on several studies focused on the natural history of HIV among women including the HERS (HIV Epidemiology Research Study) and HIV prevention among U.S. women at high risk for infection, HPTN 064 trial. 

  • Investigator of Record, HPTN 064
  • Investigator of Record, HPTN 083

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More